7:50 am Morning Refreshments
8:50 am Chair’s Opening Remarks
DEVELOPING NOVEL AI MODELS TO DETECT RETINAL DISEASE BIOMARKERS FOR FASTER, MORE ACCURATE & OBJECTIVE DATA ANALYSIS & PATIENT STRATIFICATION
9:00 am Panel Discussion: Improving Patient Care with the Help of Personalised Medicine Through AI for the Diagnosis & Optimization of the Right Patients for Clinical Trials
Synopsis
- Understanding characteristics of retinal imaging and artificial intelligence that may help identify the right patients for clinical trials
- Utilizing different imaging tools for treatment and management of patients – different imaging modalities and which ones are more appropriate for different Ophthalmic disease states
- Using AI to improve patient care by sequencing data and linking imaging databases to diagnosis the right patients for the right type of treatment
9:30 am AI in the Management of AMD from Clinical Trial to Real World
Synopsis
- The path of development, validation and regulatory approval for fully-automated algorithms
- Introduction of novel biomarkers and endpoints into clinical studies in the era of AI-empowered reading centers
- Using automated precision tools for screening, monitoring and prediction in clinical routine
10:00 am Morning Break
11:00 am Using Advanced Image Analysis for More Efficient Drug Development for Retinal Diseases
Synopsis
- Examining the value of AI in data analysis along drug development
- Linking information extracted from AI-based predictions to better define patient population, earlier disease detection and faster therapeutic intervention
- Exploring BI partnerships to leverage AI-based predictive analytics
11:30 am Artificial Intelligence for Clinical Trials in Retinal Diseases
Synopsis
- Identifying challenges and hurdles in clinical trials for drug development that can be positively impacted by AI-based tools
- Using AI-based tools to extract scientific insights, enable better disease characterization, and predict disease progression
- Considerations on implementation of AI-based tools in clinical trials
12:00 pm Lunch & Networking Break
UNCOVERING NOVEL IMAGING & BIOMARKER TECHNOLOGIES & IMPROVED DATA ANALYSIS ACROSS MULTI-MODAL IMAGING DATA
1:00 pm Demonstrating How Novel Imaging & Biomarker Technologies Enhance Early Clinical Interpretation
Synopsis
- Sharing clinical data from trials for Dry AMD, retinal detachment and glaucoma
- Assessing the practical application of imaging technologies, such as AST and DARC, in clinical development
- Determining the regulatory pathway to support broader application of novel imaging technologies
1:30 pm Multiplex Analysis of Clinical Imaging & Biomarker Data to Validate Novel Endpoints for Diabetic Retinopathy
Synopsis
- Discussing the diagnostic value of ocular fluid biomarkers
- Assessing the value of multimodal imaging in diabetic retinopathy
- Planning phase III clinical studies diabetic retinopathy
CROSS-UTILIZATION OF RETINAL IMAGING DEVICES FOR DIAGNOSIS OF NEUROLOGICAL & DISORDERS
2:00 pm Utilizing Retinal Imaging for Earlier Detection & Disease Progression of Neurological Disorders
Synopsis
- Assessing the correlation between OCT with MRI in the brain to predict neurodegeneration in multiple sclerosis
- Using the visual assessments for preclinical testing for neuroprotective strategies in multiple sclerosis
- Exploring the relevance of visual imaging for early detection of multiple sclerosis